Search | Biogen

Biogen Idec Increases Offer to Acquire Facet Biotech to $17.50 Per Share in Cash; Sends Letter to Facet Biotech Stockholders Describing Its Best-and-Final Offer

Form SC TO-T/A

Form PX14A6G

CORRECTING and REPLACING Biogen Idec to Present at the 2009 Annual Credit Suisse Healthcare Conference

Biogen Idec to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

Form 4

Form 4

Form 4

Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn’s Disease

Form 10-Q